Plasmaperfusion on Triptophan Columns Can Improve the Clinical Outcome of Patients Affected with Myasthenia Gravis

Figures & data

Figure 1. Mechanisms of PP selective molecule binding: physico‐chemical interaction.

Figure 2. Mechanisms of PP selective molecule binding: biological interaction.

Table 1. Patients' clinical profile

Patients	Age	Years of disease	Thyms histology	Prednisone mg/alt‐days	Azathioprine (mg)	Previous plasma exchange	Plasma perfusion
1F	36	5	atrophy	80/25	–	–	3
2F	36	13	hyperplasia	100/25	100	14	6
3F	43	15	hyperplasia	80/25	100	–	6
4F	23	6	hyperplasia	75/25	–	25	6
5M	45	13	thymoma	75/25	150	35	3
6F	45	10	hyperplasia	100/25	–	10	6
7F	37	6	atrophy	100/25	100	–	6
8M	33	15	hyperplasia	75/25	100	8	6

Table 2. Evaluative test used

Functional tests	Laboratory tests
Muscular tests	Anti‐AchR Ab
Respiratory function	Immunoglobulins
Electromyography	Immune complexes

Figure 3. Decrease in serum concentration of immunological markers by each perfusion cycle.

Figure 4. Decrease in serum concentration of immunological markers after all plasma perfusion sessions in all patients.